Last reviewed 01/2021
Ramipril is an ACE-inhibitor. Two important clinical trials involving the use of ramipril were the AIRE study and the HOPE study.
Indications for ramipril include:
- reducing the risk of myocardial infarction, stroke, cardiovascular death or need for revascularisation procedures in patients of 55 years or over who have clinical evidence of cardiovascular disease
- reducing the risk of myocardial infarction, stroke, cardiovascular death or need for revascularisation procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings (hypertension, high total cholesterol (>5.2 mmol/l), low HDL (<0.9mmol/l), current smoker, known microalbuminuria, clinical evidence of previous vascular disease
- mild to moderate hypertension
- congestive heart failure - may be used as adjunctive therapy to diuretics with or without cardiac glycosides
The summary of product characteristics should be consulted before prescribing this drug.
Diabetes Reduction Assesment with Ramipril and Rosiglitazone Medication (DREAM) trial